Cannabinoids are a group of chemical compounds that come from the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have suggest that it has anti inflammatory effects when induced in animals. Tetrahydrocannabinol (THC) is another one of these compounds that wields a psychotropic effect in animals. Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow cannabinoids to bind and do their job in the body. This paper will look at how cannabinoids can inhibit motility and secretion in the intestine and also how they can be made into products to help with the anti inflammation fight.
Here is the full scientific article if you wish to download it.
Cannabinoids inhibit motility and secretion in the intestine
Cannabinoids promote motility and secretion in the intestine. Cannabinoids have been give the role of preventing inflammation, indicating that drugs targeting the endogenous cannabinoid system could be tampered with for inflammatory bowel disease.
Inflammatory bowel diseases (IBDs) such as ulcerative colitis and Crohn’s disease impacts over a million people in the United States. A lot of these people are in pain from diarrhea and poor functioning digestive systems, and in up to half of those with IBD, the disease is so bad that it actually needs medical attention to get rid of the impacted bowel part. Despite current therapeutic developments and more advance knowledge of the underlying pathologies, people with IBD are often not compliant to treatment, making the look for new therapeutic methods hard. Although the actions underlying ulcerative colitis and Crohn’s disease are quite opposite, they are clokial one pathological factor: chronic inflammation.
Cannabinoids can reduce inflammation
This discovery may promote a new therapeutic method to IBD. CB1 receptors in the brain control the addictive psychological impacts of cannabis, so treating a chronic disease with an agent that directly spurs on the CB1 receptors would be widely disputed. Recent studies have shown that drugs which target endogenous cannabinoids might not have the same potential for addiction. A strong cannabinoid-like anti anxiety impact was seen in mice without making many of the other behavioral impacts of psychoactive cannabinoids.